The Compound · News
Zepbound for teens: what SURMOUNT-ADOLESCENTS found
Zepbound (tirzepatide) cut BMI by 18.5% in teenagers with obesity over 72 weeks, against a 0.5% rise on placebo. The full SURMOUNT-ADOLESCENTS results came out in JAMA on November 15 and were presented at ObesityWeek 2026. It is the strongest adolescent obesity drug result published so far. It is also not an approval.
What SURMOUNT-ADOLESCENTS found
Lilly randomized 160 adolescents aged 12 to under 18 at 31 sites in six countries. To qualify, a teen needed obesity, or overweight plus at least one weight-related condition. Two thirds got weekly tirzepatide (109 teens) and one third got placebo (51). Everyone also got diet and activity counseling. Tirzepatide started at 2.5 mg and stepped up every four weeks to the highest dose each teen could tolerate: 5, 10, or 15 mg. By week 72, 61.6% of the tirzepatide group was on 15 mg, the same top dose adults use.
All ten key secondary outcomes were statistically significant. Waist size shrank 16.4 cm more than on placebo. Teens also scored better on a weight-related quality of life scale, mostly on physical comfort.
Zepbound teen results: 18.5% or 21.4%?
Lilly's press release says Zepbound lowered BMI by 21.4%. JAMA leads with 18.5%. Both come from the same trial. The difference is who gets counted.
The 18.5% figure counts every teen who was randomized, including the ones who stopped the drug. That is the trial's primary result. The 21.4% figure estimates what would have happened if everyone stayed on treatment. Companies almost always headline the bigger number. For a parent trying to guess what will happen to their own kid, 18.5% is the more honest starting point, because some teens will stop.
| Outcome (week 72) | Tirzepatide | Placebo |
|---|---|---|
| BMI change, everyone randomized | −18.5% | +0.5% |
| BMI change, stayed on treatment | −21.4% | +0.4% |
| Body weight change | −16.9% (−17.8 kg) | +2.2% (+2.3 kg) |
| BMI down 10% or more | 71.4% | 19.5% |
| BMI down 20% or more | 48.1% | 7.9% |
| Quit due to side effects | 9.3% | 0% |
Side effects in teenagers
This is where the trial gets less comfortable. Gastrointestinal side effects hit 81.5% of teens on tirzepatide versus 54.9% on placebo. Half the tirzepatide group vomited at least once (50.9% vs 13.7%). Half had nausea. Diarrhea was 45.4% versus 25.5%. Those rates run higher than in the adult SURMOUNT trials, and 9.3% of teens quit because of them. Nobody on placebo quit for side effects.
Serious adverse events were 7.4% on tirzepatide and 3.9% on placebo. There were no deaths. Depression or suicidal thoughts were reported in 4.6% of the tirzepatide group versus 2.0% on placebo, with no severe cases. The trial was too small to say whether that gap is real. On the question parents usually ask first: growth and puberty progressed similarly in both groups over 72 weeks.
How tirzepatide compares with Wegovy in teens
The obvious benchmark is STEP TEENS, the 2022 trial that got Wegovy approved for ages 12 and up. In 201 adolescents, semaglutide 2.4 mg cut BMI by 16.1% at 68 weeks versus a 0.6% rise on placebo. About 37% lost 20% or more of their BMI. GI side effects hit 62% versus 42%.
Line those up and tirzepatide looks a few points stronger, with more GI side effects. That matches the adult picture, where tirzepatide beat semaglutide head to head in SURMOUNT-5. But nobody has run that comparison in teens. These two trials differ in length, size, and who enrolled. SURMOUNT-ADOLESCENTS had only one participant with type 2 diabetes and little racial or ethnic diversity. Treat the gap as a hint. Our semaglutide vs tirzepatide page covers the adult evidence in full.
Is Zepbound approved for teens yet?
Current status, November 16, 2026
- Zepbound is FDA approved for weight management in adults only
- Lilly has not announced an FDA filing date for adolescents
- A second trial, SURMOUNT-ADOLESCENTS-2, is testing teens with obesity and related conditions
- Lilly is also running a trial in children aged 6 to under 12. Novo's semaglutide results in that age group are in our STEP Young breakdown
- Wegovy and Saxenda are the GLP-1 drugs currently approved for obesity at age 12+
A doctor can legally prescribe Zepbound off label to a teenager, but insurance coverage for an off-label pediatric use is rare. Most online GLP-1 programs only treat adults, so this is a conversation for a pediatrician or a pediatric obesity clinic, not a telehealth form.
What it means for families and cost
The result matters because teen obesity tends to follow people into adulthood, and lifestyle programs alone rarely move BMI by more than a few percent. A drug that gets half of treated teens below the obesity line in 72 weeks changes what pediatric care can offer.
The open question is duration. The trial stopped at 72 weeks. Adult data shows most weight comes back after stopping a GLP-1, and nobody yet knows what years of tirzepatide do to a body that is still growing. Price matters too, because a teen who starts may stay on it for a long time. For adults, our breakdown of what tirzepatide costs online and the GLP-1 cost comparison show where monthly pricing sits right now.
Frequently Asked Questions
Sources
- JAMA: Tirzepatide in Adolescents With Obesity, The SURMOUNT-ADOLESCENTS Randomized Clinical Trial (published online November 15, 2026)
- Eli Lilly: Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026 (November 14, 2026)
- ClinicalTrials.gov: SURMOUNT-ADOLESCENTS, tirzepatide once weekly in adolescents (NCT06075667)
- ClinicalTrials.gov: SURMOUNT-ADOLESCENTS-2, tirzepatide in adolescents with obesity and comorbidities (NCT06439277)
- Weghuber et al. Once-Weekly Semaglutide in Adolescents with Obesity (STEP TEENS), N Engl J Med 2022
- HCPLive: STEP TEENS, semaglutide 2.4 mg weight loss benefits translate to adolescent populations